New liposomal irinotecan combo takes on pancreatic cancer in major trial
NCT ID NCT07238283
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase III trial is testing whether a new combination of drugs (irinotecan liposome, oxaliplatin, 5-fluorouracil, and calcium folinate) works better than the current standard treatment (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who haven't had prior treatment. About 662 participants will be enrolled across multiple centers. The main goal is to see if the new combo helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Irinotecan hydrochloride liposome injection (II) combined with oxaliplatin, 5-fluorouracil, and calcium folinate
What this could lead to
If this works, it could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving survival compared to current standard therapy.
What could go wrong
This is a large Phase III trial, but the new combo may not prove better or safer than the existing regimen. Pancreatic cancer is very hard to treat, so even if successful, benefits may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact